Translational Oncology,
Journal Year:
2021,
Volume and Issue:
16, P. 101312 - 101312
Published: Dec. 16, 2021
Histone
deacetylases
(HDACs)
are
enzymes
that
play
a
key
role
in
the
epigenetic
regulation
of
gene
expression
by
remodeling
chromatin.
Inhibition
HDACs
is
prospective
therapeutic
approach
for
reversing
alteration
several
diseases.
In
preclinical
research,
numerous
types
HDAC
inhibitors
were
discovered
to
exhibit
powerful
and
selective
anticancer
properties.
However,
such
research
has
revealed
effects
may
be
far
broader
more
intricate
than
previously
thought.
This
review
will
provide
insight
into
their
mechanism
action
with
special
emphasis
on
significance
treatment
Chronic
Obstructive
Pulmonary
Disease
lung
cancer.
Nanocarrier-mediated
inhibitor
delivery
new
approaches
targeting
also
discussed.
Signal Transduction and Targeted Therapy,
Journal Year:
2021,
Volume and Issue:
6(1)
Published: May 31, 2021
Abstract
Due
to
the
advantages
in
efficacy
and
safety
compared
with
traditional
chemotherapy
drugs,
targeted
therapeutic
drugs
have
become
mainstream
cancer
treatments.
Since
first
tyrosine
kinase
inhibitor
imatinib
was
approved
enter
market
by
US
Food
Drug
Administration
(FDA)
2001,
an
increasing
number
of
small-molecule
been
developed
for
treatment
malignancies.
By
December
2020,
89
antitumor
FDA
National
Medical
Products
(NMPA)
China.
Despite
great
progress,
anti-cancer
still
face
many
challenges,
such
as
a
low
response
rate
drug
resistance.
To
better
promote
development
we
conducted
comprehensive
review
according
target
classification.
We
present
all
well
important
candidates
clinical
trials
each
target,
discuss
current
provide
insights
perspectives
research
drugs.
Frontiers in Oncology,
Journal Year:
2018,
Volume and Issue:
8
Published: March 29, 2018
Genetic
and
epigenetic
changes
in
DNA
are
involved
cancer
development
tumor
progression.
Histone
deacetylases
(HDACs)
key
regulators
of
gene
expression
that
act
as
transcriptional
repressors
by
removing
acetyl
groups
from
histones.
HDACs
dysregulated
many
cancers,
making
them
a
therapeutic
target
for
the
treatment
cancer.
HDAC
inhibitors
(HDACi),
novel
class
small-molecular
therapeutics,
now
approved
Food
Drug
Administration
anticancer
agents.
While
they
have
shown
great
promise,
resistance
to
HDACi
is
often
observed
furthermore,
limited
success
treating
solid
tumors.
The
combination
with
standard
chemotherapeutic
drugs
has
demonstrated
promising
effects
both
preclinical
clinical
studies.
In
this
review,
we
summarize
research
thus
far
on
therapy,
other
anti-cancer
agents
their
translation
into
We
additionally
highlight
side
associated
therapy
discuss
potential
biomarkers
either
select
or
predict
patient's
response
these
agents,
order
limit
off-target
toxicity
HDACi.
Genome biology,
Journal Year:
2019,
Volume and Issue:
20(1)
Published: Nov. 20, 2019
Abstract
The
epigenetic
modifications
of
histones
are
versatile
marks
that
intimately
connected
to
development
and
disease
pathogenesis
including
human
cancers.
In
this
review,
we
will
discuss
the
many
different
types
histone
biological
processes
with
which
they
involved.
Specifically,
review
enzymatic
machineries
involved
in
cancer
progression,
how
apply
currently
available
small
molecule
inhibitors
for
modifiers
as
tool
compounds
study
functional
significance
their
clinical
implications.
Nature Communications,
Journal Year:
2018,
Volume and Issue:
9(1)
Published: Jan. 3, 2018
Abstract
The
recently
discovered
histone
post-translational
modification
crotonylation
connects
cellular
metabolism
to
gene
regulation.
Its
regulation
and
tissue-specific
functions
are
poorly
understood.
We
characterize
in
intestinal
epithelia
find
that
H3
at
lysine
18
is
a
surprisingly
abundant
the
small
intestine
crypt
colon,
linked
show
this
highly
dynamic
regulated
during
cell
cycle.
identify
class
I
deacetylases,
HDAC1,
HDAC2,
HDAC3,
as
major
executors
of
decrotonylation.
known
HDAC
inhibitors,
including
gut
microbiota-derived
butyrate,
affect
Consistent
with
this,
we
depletion
microbiota
leads
global
change
colon.
Our
results
suggest
chromatin
microbiota,
least
part,
via
short-chain
fatty
acids
HDACs.
Molecular Metabolism,
Journal Year:
2019,
Volume and Issue:
33, P. 102 - 121
Published: July 27, 2019
Cancer
is
one
of
the
greatest
public
health
challenges
worldwide,
and
we
still
lack
complementary
approaches
to
significantly
enhance
efficacy
standard
anticancer
therapies.
The
ketogenic
diet,
a
high-fat,
low-carbohydrate
diet
with
adequate
amounts
protein,
appears
sensitize
most
cancers
treatment
by
exploiting
reprogramed
metabolism
cancer
cells,
making
promising
candidate
as
an
adjuvant
therapy.To
critically
evaluate
available
preclinical
clinical
evidence
regarding
in
context
therapy.
Furthermore,
highlight
important
mechanisms
that
could
explain
potential
antitumor
effects
diet.The
probably
creates
unfavorable
metabolic
environment
for
cells
thus
can
be
regarded
patient-specific
multifactorial
majority
several
studies
argue
use
combination
therapies
based
on
its
classic
chemo-
radiotherapy,
overall
good
safety
tolerability
increase
quality
life.
However,
further
elucidate
therapy
application
practice,
more
molecular
well
uniformly
controlled
trials
are
needed.
Frontiers in Cell and Developmental Biology,
Journal Year:
2021,
Volume and Issue:
8
Published: Jan. 12, 2021
Metabolic
reprogramming
has
been
widely
recognized
as
a
hallmark
of
malignancy.
The
uptake
and
metabolism
amino
acids
are
aberrantly
upregulated
in
many
cancers
that
display
addiction
to
particular
acids.
Amino
facilitate
the
survival
proliferation
cancer
cells
under
genotoxic,
oxidative,
nutritional
stress.
Thus,
targeting
acid
is
becoming
potential
therapeutic
strategy
for
patients.
In
this
review,
we
will
systematically
summarize
recent
progress
malignancy
discuss
their
interconnection
with
mammalian
target
rapamycin
complex
1
(mTORC1)
signaling,
epigenetic
modification,
tumor
growth
immunity,
ferroptosis.
Finally,
highlight
applications.
International Journal of Oral Science,
Journal Year:
2023,
Volume and Issue:
15(1)
Published: Sept. 22, 2023
Oral
squamous
cell
carcinoma
(OSCC)
develops
on
the
mucosal
epithelium
of
oral
cavity.
It
accounts
for
approximately
90%
malignancies
and
impairs
appearance,
pronunciation,
swallowing,
flavor
perception.
In
2020,
377,713
OSCC
cases
were
reported
globally.
According
to
Global
Cancer
Observatory
(GCO),
incidence
will
rise
by
40%
2040,
accompanied
a
growth
in
mortality.
Persistent
exposure
various
risk
factors,
including
tobacco,
alcohol,
betel
quid
(BQ),
human
papillomavirus
(HPV),
lead
development
potentially
malignant
disorders
(OPMDs),
which
are
lesions
with
an
increased
developing
into
OSCC.
Complex
multifactorial,
oncogenesis
process
involves
genetic
alteration,
epigenetic
modification,
dysregulated
tumor
microenvironment.
Although
therapeutic
interventions,
such
as
chemotherapy,
radiation,
immunotherapy,
nanomedicine,
have
been
proposed
prevent
or
treat
OPMDs,
understanding
mechanism
facilitate
identification
prognostic
thereby
improving
efficacy
treatment
patients.
This
review
summarizes
mechanisms
involved
Moreover,
current
interventions
methods
OPMDs
discussed
comprehension
provide
several
prospective
outlooks
fields.
Genes,
Journal Year:
2020,
Volume and Issue:
11(5), P. 556 - 556
Published: May 15, 2020
Histone
deacetylases
(HDACs)
are
evolutionary
conserved
enzymes
which
operate
by
removing
acetyl
groups
from
histones
and
other
protein
regulatory
factors,
with
functional
consequences
on
chromatin
remodeling
gene
expression
profiles.
We
provide
here
a
review
the
recent
knowledge
accrued
zinc-dependent
HDAC
family
across
different
species,
tissues,
human
pathologies,
specifically
focusing
role
of
inhibitors
as
anti-cancer
agents.
will
investigate
chemical
specificity
HDACs
discuss
their
in
interactome
members
chromatin-binding
complexes.